Hits, Misses & Key Firsts For EMA's PRIME Scheme :: Pink Sheet
Pfizer 2018: Blockbusters and biosimilars – PharmaLive
NICE recommends cannabinoid med for severe epilepsy | pharmaphorum
Drug repurposing: progress, challenges and recommendations | Nature Reviews Drug Discovery
Open Letter to J&J: Calling for affordable access to critical TB drug bedaquiline | Médecins Sans Frontières Access Campaign
Biopharmaceutical benchmarks 2018 | Nature Biotechnology
2018 ISPE Annual Meeting & Expo | ISPE | International Society for Pharmaceutical Engineering
Intelligent packaging: combating counterfeits and extending drug lifespan
Thinking Outside the Box—Novel Antibacterials To Tackle the Resistance Crisis - Lakemeyer - 2018 - Angewandte Chemie International Edition - Wiley Online Library
Why Are There Only 11 Cell and Gene Therapies in Europe?
Frontiers | Labeling of Disease-Modifying Therapies for Neurodegenerative Disorders
Public consultation on key principles for the electronic product information of EU medicines | European Medicines Agency
Microorganisms | Free Full-Text | Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
6 pharma trends for 2018 that will shape the industry
TIF.ACCESS Project – TIF
What is IDMP? - tepsivo.com
European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure
EMA Acknowledges Persistent Sexual Dysfunction After SSRIs & SNRIs | RxISK
IRIS guide to registration and RPIs v2.12
Eculizumab - Wikipedia
What Can the U.S. Learn from Rx Spending Controls in France? | Commonwealth Fund
State of emergency medicine in Indonesia - Yusvirazi - 2018 - Emergency Medicine Australasia - Wiley Online Library
Why Are There Only 11 Cell and Gene Therapies in Europe?
